Collegium Pharmaceutical, Inc. /
Ironshore Therapeutics Inc.
Collegium Pharmaceutical adds Ironshore Therapeutics to its portfolio
What happened
Collegium Pharmaceutical, Inc. completed its acquisition of Ironshore Therapeutics Inc. on September 3, 2024. Ironshore markets and distributes Jornay PM, a treatment for attention deficit hyperactivity disorder.
The deal included $525 million in cash, with an additional $25 million payable if Jornay PM net revenue exceeds a defined threshold in 2025.
The source
Everything on this page comes from the source below.
Collegium Pharmaceutical adds Ironshore Therapeutics to its portfolio
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly